Bcl-xL inhibition - a novel strategy for glioma therapy

Por Karpel-Massler, Georg, Siegelin, Markus D.
Publicado no Aging (Albany NY) (2016)

TIC10/ONC201—a potential therapeutic in glioblastoma

Por Karpel-Massler, Georg, Siegelin, Markus D.
Publicado no Transl Cancer Res (2017)

A triple drug combination as a novel anti-glioma therapy?

Por Zhang, Yiru, Karpel-Massler, Georg, Siegelin, Markus D.
Publicado no Oncotarget (2018)

CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous...

Por Kast, Richard E., Karpel-Massler, Georg, Halatsch, Marc-Eric
Publicado no Oncotarget (2014)

BET-inhibitors as sensitizers for BH3-mimetics

Por Ishida, Chiaki Tsuge, Karpel-Massler, Georg, Siegelin, Markus D.
Publicado no Aging (Albany NY) (2017)

IDH1 R132H predicts sensitivity to Bcl-xL inhibition-mediated programmed cell death

Por Karpel-Massler, Georg, Ishida, Chiaki Tsuge, Siegelin, Markus D.
Publicado no Oncotarget (2017)

CBMT-37. FDA-APPROVED HDAC INHIBITORS ANTAGONIZE THE WARBURG EFFECT AND CAUSE UNIQUE METABOLIC VULNERABILITIES

Por Zhang, Yiru, Ishida, Chiaki, Karpel-Massler, Georg, Siegelin, Markus
Publicado no Neuro Oncol (2018)

Ribozyme-Mediated Inhibition of 801-bp Deletion-Mutant Epidermal Growth Factor Receptor mRNA Expression in Glioblastoma Multiforme

Por Karpel-Massler, Georg, Wirtz, Christian Rainer, Halatsch, Marc-Eric
Publicado no Molecules (2010)

RARE-09. MINIMALLY TOXIC MULTIMODAL AND POLYPHARMACOLOGICAL THERAPY IN TREATMENT OF DIFFUSE MIDLINE GLIOMA

Por Salacz, Michael, Halatsch, Marc-Eric, Karpel-Massler, Georg, Kast, Richard
Publicado no Neuro Oncol (2017)

Novel IDH1 Targeted Glioma Therapies

Por Karpel-Massler, Georg, Nguyen, Trang, Shang, Enyuan, Siegelin, Markus D.
Publicado no CNS Drugs (2019)

ET-26 COMBINED TREATMENT WITH ABT263 AND GX15-070 YIELDS A SYNERGISTIC ANTIPROLIFERATIVE EFFECT IN GLIOBLASTOMA

Por Karpel-Massler, Georg, Halatsch, Marc-Eric, Westhoff, Mike-Andrew, Siegelin, Markus David
Publicado em 2014

EXTH-79. INITIAL EXPERIENCES WITH COMPASSIONATE-USE CUSP9v3/v4 FOR RECURRENT GLIOBLASTOMA

Por Halatsch, Marc-Eric, Salacz, Michael, Schmitz, Bernd, Karpel-Massler, Georg, Kast, Richard
Publicado no Neuro Oncol (2017)

Metabolic Reprogramming by c-MET Inhibition as a Targetable Vulnerability in Glioblastoma

Por Thi Thu Nguyen, Trang, Shang, Enyuan, Karpel-Massler, Georg, Siegelin, Markus D.
Publicado no Oncoscience (2020)

Killing Me Softly—Future Challenges in Apoptosis Research

Por Westhoff, Mike-Andrew, Brühl, Oliver, Nonnenmacher, Lisa, Karpel-Massler, Georg, Debatin, Klaus-Michael
Publicado em 2014

Epidermal to Mesenchymal Transition and Failure of EGFR-Targeted Therapy in Glioblastoma

Por Pala, Andrej, Karpel-Massler, Georg, Kast, Richard Eric, Wirtz, Christian Rainer, Halatsch, Marc-Eric
Publicado em 2012

Blocking epithelial-to-mesenchymal transition in glioblastoma with a sextet of repurposed drugs: the EIS regimen

Por Kast, Richard E, Skuli, Nicolas, Karpel-Massler, Georg, Frosina, Guido, Ryken, Timothy, Halatsch, Marc-Eric
Publicado no Oncotarget (2017)

Cell death-based treatment of childhood cancer

Por Westhoff, Mike-Andrew, Marschall, Nicolas, Grunert, Michael, Karpel-Massler, Georg, Burdach, Stefan, Debatin, Klaus-Michael
Publicado no Cell Death Dis (2018)

EXTH-45. THE REPURPOSED CUSP9 REGIMEN EXERTS POTENT ANTI-NEOPLASTIC ACTIVITY AGAINST GLIOBLASTOMA CELLS IN VITRO

Por Halatsch, Marc-Eric, Kast, Richard Eric, Dwucet, Annika, Siegelin, Markus, Heiland, Tim, Karpel-Massler, Georg
Publicado no Neuro Oncol (2018)

Epigenetic Targeting of Mcl-1 Is Synthetically Lethal with Bcl-xL/Bcl-2 Inhibition in Model Systems of Glioblastoma

Por Shang, Enyuan, Nguyen, Trang T. T., Shu, Chang, Westhoff, Mike-Andrew, Karpel-Massler, Georg, Siegelin, Markus D.
Publicado no Cancers (Basel) (2020)

Toward a noncytotoxic glioblastoma therapy: blocking MCP-1 with the MTZ Regimen

Por Salacz, Michael E, Kast, Richard E, Saki, Najmaldin, Brüning, Ansgar, Karpel-Massler, Georg, Halatsch, Marc-Eric
Publicado no Onco Targets Ther (2016)